Opicapone

Drug Profile

Opicapone

Alternative Names: BIA-91067; Ongentys; ONO-2370

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator BIAL
  • Developer BIAL; Ono Pharmaceutical
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 10 Feb 2017 Opicapone licensed to Neurocrine Biosciences in USA and Canada
  • 10 Feb 2017 Updated efficacy and adverse events data from the BIPARK I and II trials in Parkinson's disease released by BIAL
  • 09 Feb 2017 Launched for Parkinson's disease (Adjunctive treatment) in Germany (PO) prior to February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top